Drug Trial Radar · NCT05466422
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Sep 20, 2022
Primary completion
Jul 3, 2025
Study completion Jul 3, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jul 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-2214 in adults with mild cognitive impairment or mild-to-moderate Alzheimer's Disease. The primary hypothesis (Part 1) is that at a generally well-tolerated dose level, the true geometric mean concentration at Day 85 of MK-2214 in cerebrospinal fluid is \>0.3 nanomolar
Conditions
- Alzheimer Disease
Interventions
MK-2214Biological
IV infusion
PlaceboDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 297 days
- Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 57 days
- Area Under the Concentration-Time Curve From Time 0 to 28 Days (AUC0-28) of MK-2214 in Serum After First Dose (Day 1)Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post first dose (Day 1), Day 4, Day 8, Day 15, and predose on Day 29
- AUC0-28 of MK-2214 in Serum After Third Dose (Day 57)Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297
- Maximum Serum Concentration (Cmax) of MK-2214 After First Dose (Day 1)Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post first dose (Day 1), Day 4, Day 8, Day 15, and predose on Day 29
- Cmax of MK-2214 After Third Dose (Day 57)Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297
- Time of Maximum Serum Concentration (Tmax) of MK-2214 After First Dose (Day 1)Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post first dose (Day 1), Day 4, Day 8, Day 15, and predose on Day 29
- Tmax of MK-2214 After Third Dose (Day 57)Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297
- Apparent Half-Life (T1/2) of MK-2214 in Serum After Third Dose (Day 57)Time frame: Predose, 0.5, 1, 2, 4, 8, 12, and 24 hours post third dose (Day 57), Day 60, Day 64, Day 71, Day 85, Day 141, Day 197, Day 247, and Day 297
- Concentration of MK-2214 in Cerebrospinal Fluid (CSF) at Day 85Time frame: Day 85
- Free Phospho-Tau Concentration in CSFTime frame: Day 85
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
California Clinical Trials Medical Group managed by PAREXEL-PAREXEL International ( Site 0007)
Glendale, California
Collaborative Neuroscience Research, LLC ( Site 0009)
Los Alamitos, California
NRC Research Institute ( Site 0015)
Orange, California
Velocity Clinical Research, Hallandale Beach ( Site 0001)
Hallandale, Florida
Research Centers of America ( Hollywood ) ( Site 0004)
Hollywood, Florida
K2 Medical Research ( Site 0005)
Maitland, Florida
Charter Research - Winter Park ( Site 0012)
Orlando, Florida
Progressive Medical Research-Alzheimer's Team ( Site 0013)
Port Orange, Florida
Charter Research - Lady Lake ( Site 0011)
The Villages, Florida
CenExel iResearch, LLC ( Site 0002)
Decatur, Georgia
Global Medical Institutes LLC; Princeton Medical Institute ( Site 0003)
Princeton, New Jersey
Neuro-Behavioral Clinical Research ( Site 0016)
North Canton, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.